| Thanks to SoCalBio Weekly Update Sponsor |
Join us in June SoCalBio/Image 2000 Golf Classic
Title Sponsor
 Benefiting When: June 28, 2010Time: 10:00am - 8:30pm Where: Old Ranch Country Club, Seal Beach, California |
Join SoCalBioJoin well-known entrepreneur Alfred Mann and other SoCalBio leaders to promote the biotech and device industries in the Greater Los Angeles Metro Area for job creation and overall economic growth. |  |
|
| April 5, 2010  | |
| Featured Resource | Learn About the GAP Program at UCLA
  Directed by Robert Foster, (Photo right), the Global Access Program (GAP) at the UCLA Anderson School of Management was founded in 1998 and has since worked with over 328 international technology companies in ten countries. GAP is a unique educational program that matches a team of students from the Fully Employed MBA
(FEMBA) program with existing international technology companies to develop a comprehensive business strategy that enables the companies to move to the next stage of their corporate development.... Learn how your company can benefit |
 |  |
| Upcoming SoCalBio Events | SoCalBio Executive Roundtable Discussion
Regenerative Medicine Luncheon and Discussion
(Open only to executives and managers in regenerative medicine companies)
Date: April 6, 2010
Time 11:00 am - 2:00 pm
Location: Offices of Reed Smith in Downtown Los Angeles
By Invitation Only (for more info, contact SoCalBio at scbc@socalbio.org or call 213-236-4890)
*************************************************
SoCalBio HR Symposium
Best Practices in Designing Wellness Programs
Join us to learn how to craft wellness programs to improve employee health, reduce medical claims, and guarantee a return on investment (Open only to HR professionals in medical device, IVD, biotech and generic pharma firms)
Date: April 15, 2010
Time: 9:00 am - 1:30 pm
Location: Four Seasons Hotel in Westlake Village
By Invitation Only (for more info, contact SoCalBio at scbc@socalbio.org or call 213-236-4890)
Join the SoCalBio HR Network on LinkedIn
*************************************************
SoCalBio Networking Forum in Los Angeles
Trends in Ophthalmology
Exploring the frontier of innovation in ophthalmic products, drugs and devices conceived and commercialized in Southern California
*************************************************
SoCalBio Regulatory Best Practice Workshop
The Shifting Paradigm in FDA Process Validation
This SoCalBio workshop focuses on the FDA's guidelines regarding Process Validation. It is designed for device and pharma regulatory affairs professionals to learn what is required to approach process validation from a life cycle perspective and incorporates modern risk management and quality systems tools and concepts. |
| |
| Welcome New SoCalBio Members | Nanogea (Weslake Village)
 Nanogea is a
nano-bioscience company focused on commercializing a sensitive single molecular detection platform based on its NanoCone chemistry and NanoCone Enabled Atomic Force technology.. Learn more
Arrowhead Research Corporation (Pasadena)
 Arrowhead Research Corporation is a holding company that forms, acquires, and operates portfolio companies commercializing innovative
nanotechnologies. By working closely with leading scientists and universities, Arrowhead identifies the latest advances in nanotechnology and matches them with product development opportunities in high-growth markets... Learn more
Eichleay Engineers Inc. (Long
Beach)
 Eichleay Engineers Inc. of California and Eichleay Engineers Inc. of Southern California offer a broad range of engineering, procurement, project management, and client staff augmentation services to the life science, high technology, petroleum refining, chemical, food and beverage, and manufacturing industries... Learn More
 RCRI was founded in 1999 and has become one of the nation's largest contract research organizations
(CROs) assisting medical device, biologics, and in vitro diagnostic medical product firms obtain market releases from regulatory authorities. RCRI was one of the first CROs to obtain ISO 9001:2000 certification to provide expertise in regulatory affairs, clinical trial design and management, reimbursement strategies, health economics, quality systems,
Biostatistics, and venture capital due-diligence... Learn more |
| IP Litigation | How Gene Patents Harm Innovation
Read a Forbes Magazine article on how a landmark ruling overturning Myriad Genetics' cancer gene patents lays the groundwork for a new industry... Access article
Edwards Awarded $73.5M in Medtronic Patent Case
The Irvine-based Edwards Biosciences said in a press release that the jury found that Medtronic's CoreValve business willfully infringed on a patent that relates to an artificial valve that is implanted through a catheter. Edwards said it will ask for a permanent injunction that would block Medtronic from selling the Sapien valve -- which has not been approved -- in the
U.S... Read more |
| Funding | Two Pasadena Bioscience Companies Secure $24 Million in Equity Investment
Recent SEC filings show that two Pasadena, Calif.-based bioscience companies, Aliva Biopharmaceuticals and Materia, Inc. have secured $12.8 million and $11.7 million in institutional funding respectively. Both companies are Caltech
spinoffs. Aliva is developing animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. Materia is utilizing olefin metathesis technology to develop pharmaceutical intermediaries, renewable based chemicals, specialty materials and commodity plastics.
Reverse Medical Corporation Successfully Completes Series B Financing
The Irvine-based company raised $14 million from new investors Wexford Capital, Getz Bros., BioStar Ventures, Early Stage Partners and Emergent Medical Partners. Current investors NBGI Ventures, MedFocus Funds and South Australian Life Science Advancement Partnership also participated in this
financing... Read more
|
| Partnerships | Allergan and Serenity Pharmaceuticals Enter into Global Agreement for the Treatment of Nocturia
Under the terms of the agreement, Allergan receives exclusive worldwide rights to develop, manufacture and commercialize Ser-120, a Phase III investigational drug currently in clinical development for the treatment of
nocturia, a common yet often under-diagnosed urological disorder in adults characterized by frequent urination at night time. The agreement encompasses all potential indications except Primary Nocturnal Enuresis (pediatric bedwetting). Allergan will make an upfront payment to Serenity of $43 million, potential development and regulatory milestone payments of up to $122 million, future potential sales milestones, and royalty payments on worldwide sales.... Read more |
| About SoCalBio |  SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio |
| |
|
